Form 4: Tango Therapeutics Executive Adam Crystal Sells Shares to Cover Tax Obligations

Adam Crystal, an executive at Tango Therapeutics, sold shares of common stock on February 4th and 5th, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On February 4, 2025, Adam Crystal, President, Research & Development at Tango Therapeutics, sold 7,432 shares of common stock at a weighted average price of $2.988 per share.
• The sales prices ranged from $2.86 to $3.07 per share on this date.
• Following this transaction, Crystal directly owns 165,061 shares of Tango Therapeutics.
• On February 5, 2025, Crystal sold 6,851 shares of common stock at a weighted average price of $3.1614 per share.
• The sales prices ranged from $3.00 to $3.245 per share on this date.
• Following this transaction, Crystal directly owns 158,210 shares of Tango Therapeutics.
• These sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units, according to the issuer's 'sell-to-cover' policy.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the stock sales are related to tax obligations and do not necessarily indicate a change in the executive's confidence in the company.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax obligations. These transactions are closely monitored by investors for insights into management's perspective on the company's value and future prospects.

Stakeholder Impact

• The stock sales may have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates

Keywords

Tango Therapeutics, Adam Crystal, Form 4, Stock Sale, Executive, Tax Withholding, Restricted Stock Units, TNGX